Rhenium Re 188 etidronate

Drug Profile

Rhenium Re 188 etidronate

Alternative Names: 188Re -HEDP; Etidronate-Re-188; Etidronate-Rhenium-188; Re-188-etidronate; Re-188-etidronic-acid; Re-188-HEDP; Rhenium-188-HEDP

Latest Information Update: 08 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Lai Tai Medical Biotechnology
  • Developer Jiangsu Lai Tai Medical Biotechnology; Shanghai Institute of Applied Physics Chinese Academy of Sciences
  • Class Antineoplastics; Bisphosphonates; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer pain

Most Recent Events

  • 14 Mar 2018 VU University Medical Center plans the phase III RaRe trial for Prostate cancer (Metastatic disease, Second-line therapy or greater) in Netherlands in April 2018 (NCT03458559)
  • 07 Jan 2016 Phase-II clinical trials in Cancer pain in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top